Immunogen Stock News

Wall Street is having a bad day, but shareholders in these companies are celebrating.

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer

ImmunoGen Inc (NASDAQ: IMGN) shares have gained more than 30% during premarket trading in reaction to positive topline data from the SORAYA trial of mirvetuximab soravtansine for ovarian cancer. Th

The stock price of ImmunoGen, Inc. (NASDAQ: IMGN) increased by over 25% pre-market today. This is why it happened.

ImmunoGen, Inc. (NASDAQ:IMGN)s stock price reached a new 52-week low on Monday . The stock traded as low as $4.90 and last traded at $5.00, with a volume of 9545 shares. The stock had previously closed at $5.05. IMGN has been the topic of several recent analyst reports. SVB Leerink lowered their price target on []

California State Teachers Retirement System reduced its position in ImmunoGen, Inc. (NASDAQ:IMGN) by 6.9% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 269,361 shares of the biotechnology companys stock after selling 19,964 shares during the period. California State Teachers Retirement Systems holdings in ImmunoGen were worth $1,775,000 at the end of the most recent []

Wall Street analysts predict that ImmunoGen, Inc. (NASDAQ:IMGN) will report $26.17 million in sales for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for ImmunoGens earnings, with estimates ranging from $23.10 million to $32.00 million. ImmunoGen posted sales of $85.80 million in the same quarter last year, which would []

Equities analysts forecast that ImmunoGen, Inc. (NASDAQ:IMGN) will report earnings of ($0.18) per share for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for ImmunoGens earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.24). ImmunoGen reported earnings per share of $0.16 during the same quarter last year, which indicates []

Investors need to pay close attention to ImmunoGen (IMGN) stock based on the movements in the options market lately.

ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. The company lowers its operating expense guidance for 2021.

ImmunoGen released its Q3-2021 earnings and numbers are solid. Positive expectations around SORAYA study.

ImmunoGen, Inc.'s (IMGN) CEO Mark Enyedy on Q3 2021 Results - Earnings Call Transcript

ImmunoGen (IMGN) delivered earnings and revenue surprises of 5.26% and -53.15%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Immunogen (NASDAQ:IMGN) reported its Q3 earnings results on Friday, October 29, 2021 at 06:30 AM. Here's what investors need to know about the announcement.